Shares of Moderna (MRNA) are up 7% in pre-market trading at $32.56. Last night, the company disclosed that its CEO Stephane Bancel bought 160.3K shares of common stock and Director Paul Sagan bought 31.6K shares of common stock on March 3rd in transaction sizes of $5.0M and $1.0M respectively.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna (MRNA) Stock Climbs as CEO and Director Make Strategic Insider Purchases
- HHS increasing scrutiny of vaccines under RFK Jr., WSJ reports
- Genevant, Arbutus initiate patent infringement actions against Moderna
- Dell reports mixed Q4 results, Intel delays Ohio chip factory: Morning Buzz
- Moderna receives MHRA marketing authorization for RSV vaccine